Aicha Kerassa

Dr. Aicha Kerassa

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Chemical Physics Impact
Verified
Journal Article
Open access
RMRadhia Mazri
Radhia Mazri
OMOuassaf Mebarka
Ouassaf Mebarka
AKAicha Kerassa
Aicha Kerassa
BABader Y. Alhatlani
Bader Y. Alhatlani

10 February 2024 in Molecules
Verified
Journal Article
Open access
PDF file
NDNour Elhouda Derki
Nour Elhouda Derki
AKAicha Kerassa
Aicha Kerassa
SBSalah Belaidi
Salah Belaidi
MDMaroua Derki
Maroua Derki
Imane YamariImane Yamari
Imane Yamari
SCSamir Chtita
Samir Chtita
A set of 5-(substituted benzylidene) thiazolidine-2,4-dione derivatives was explored to study the main structural requirement for the design of protein tyrosine phosphatase 1B (PTP1B) inhibitors. Utilizing multiple linear regression (MLR) analysis, we constructed a robust quantitative structure–activity relationship (QSAR) model to predict inhibitory activity, resulting in a noteworthy correlation coefficient (R2) of 0.942. Rigorous cross-validation using the leave-one-out (LOO) technique and statistical parameter calculations affirmed the model’s reliability, with the QSAR analysis revealing 10 distinct structural patterns influencing PTP1B inhibitory activity. Compound 7e(ref) emerged as the optimal scaffold for drug design. Seven new PTP1B inhibitors were designed based on the QSAR model, followed by molecular docking studies to predict interactions and identify structural features. Pharmacokinetics properties were assessed through drug-likeness and ADMET studies. After that density functional theory (DFT) was conducted to assess the stability and reactivity of potential diabetes mellitus drug candidates. The subsequent dynamic simulation phase provided additional insights into stability and interactions dynamics of the top-ranked compound 11c. This comprehensive approach enhances our understanding of potential drug candidates for treating diabetes mellitus.

1 October 2024 in STUDIES IN HEALTH SCIENCES
Verified
Journal Article
Open access
PDF file
MMMalika Mellaoui
Malika Mellaoui
Rradhia Mazri
radhia Mazri
MMMohamed Mouadh Messaoui
Mohamed Mouadh Messaoui
AKAicha Kerassa
Aicha Kerassa
OMOuassaf Mebarka
Ouassaf Mebarka
Human immunodeficiency viru (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS), a disease that severely weakens the immune system and makes patients more susceptible to infections. Although there is no definitive cure for HIV, advances in drug development offer promising prospects. In this study, we targeted HIV-1 reverse transcriptase by performing virtual screening (VS) to identify novel candidate compounds. From a database of compounds similar to the inhibitor thymidine-5'-triphosphate (TTP), three compounds (CID441663, CID123650073, and CID123789980) were selected for their docking scores, which outperformed those of the reference compound TTP (-6.2302 kcal/mol). These compounds were then subjected to ADMET, PASS, and DFT analyses. Interestingly, all three ligands showed a broad spectrum of predicted antiviral activity, including targets related to human herpes virus and HIV. Specifically, while TTP primarily targets HIV-1 reverse transcriptase, the top three ligands were predicted to target HIV-1 integrase, with CID441663 and CID123789980 displaying higher confidence in this target compared to CID123650073. These findings suggest that the candidate ligands should undergo further in vitro validation to determine their precise roles as inhibitors or antagonists, and to confirm their selective targeting of HIV-related proteins.